DOCSLIB.ORG

Gamma-Secretase Directly Sheds the Survival Receptor BCMA from Plasma Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gamma-Secretase Directly Sheds the Survival Receptor BCMA from Plasma Cells γ-secretase directly sheds the survival receptor BCMA from plasma cells Submitted by Sarah Anne Laurent st 1 of June 2015 Dissertation der Graduate School of Systemic Neurosciences der Ludwig-Maximilians-Universität München, 2015 First reviewer and supervisor: Prof. Dr. Edgar Meinl Second reviewer: Prof. Dr. Nikolaus Plesnila Third reviewer: Prof. Dr. Hermann Eibel Date of oral examination: 8th October 2015 CONTENTS Abstract ................................................................................................................................................... 1 Abbreviations .......................................................................................................................................... 3 1. Introduction ......................................................................................................................................... 5 1.1 Multiple sclerosis ..................................................................................................................... 5 1.2 Humoral immunity in MS ........................................................................................................ 6 1.3 Systemic lupus erythematosus ................................................................................................ 8 1.4 The BAFF/APRIL-system .......................................................................................................... 8 1.4.1 Structure, expression and signaling of BAFF, APRIL and their receptors ........................ 8 1.4.2 Physiological relevance of the BAFF/APRIL pathway .................................................... 11 1.4.2.1 B cell homeostasis and tolerance .............................................................................. 11 1.4.2.2 Role of BCMA in plasma cell survival and antigen presentation ............................... 11 1.4.3 The BAFF/APRIL-system in autoimmunity ..................................................................... 13 1.4.3.1 In mice ....................................................................................................................... 13 1.4.3.2 In human .................................................................................................................... 13 1.5 Soluble receptors ................................................................................................................... 14 1.5.1 Mechanisms of generations .......................................................................................... 14 1.5.1.1 Shedding .................................................................................................................... 14 1.5.1.2 Alternative splicing .................................................................................................... 15 1.5.1.3 Exosomes ................................................................................................................... 15 1.5.2 Functional relevance ..................................................................................................... 15 1.6 The γ-secretase complex ....................................................................................................... 16 1.6.1 Subunits and assembly .................................................................................................. 17 1.6.2 The role of γ-secretase in biology and disease .............................................................. 18 2 Objectives ...................................................................................................................................... 21 3 Materials and Methods ................................................................................................................. 23 3.1 Materials ................................................................................................................................ 23 3.1.1 Clinical samples ............................................................................................................. 23 3.1.2 Antibodies ...................................................................................................................... 26 3.1.3 Cytokines ....................................................................................................................... 27 3.1.4 Protease inhibitors ........................................................................................................ 28 3.1.5 ELISA .............................................................................................................................. 28 3.1.6 Reagents and buffers ..................................................................................................... 29 3.1.7 Gels ................................................................................................................................ 30 3.2 Cell culture ............................................................................................................................. 31 3.2.1 General cell culture method .......................................................................................... 31 3.2.2 Cell lines ......................................................................................................................... 31 3.2.3 Isolation of human peripheral blood mononuclear cells by density gradient centrifugation ................................................................................................................................ 32 3.2.4 Human B cell isolation ................................................................................................... 32 3.2.5 Human B cell stimulation and differentiation ............................................................... 33 3.2.5.1 CD40L/IL-21 stimulation ............................................................................................ 33 3.2.5.2 Resiquimod/IL-2 stimulation ..................................................................................... 33 3.2.6 Mouse B cell isolation and survival assay ...................................................................... 33 3.3 General protein analytics ...................................................................................................... 34 3.3.1 Cell lysates ..................................................................................................................... 34 3.3.2 Immunoprecipitation..................................................................................................... 34 3.3.2.1 Samples ..................................................................................................................... 34 3.3.2.2 Magnetic beads preparation, antibody coupling and crosslinking ........................... 35 3.3.2.3 Immunoprecipitation................................................................................................. 35 3.3.2.4 Elution ........................................................................................................................ 36 3.3.3 Gel electrophoresis, Coomassie staining and Western blot ......................................... 36 3.3.3.1 Western blot detection of soluble BCMA upon immunoprecipitation ..................... 36 3.3.3.2 Western blot detection of presenilin 1 and nicastrin................................................ 37 3.3.4 Mass spectrometric analysis and sample preparation .................................................. 37 3.3.4.1 In solution digestion by trypsin followed by mass spectrometry ............................. 37 3.3.4.2 Silver staining, in gel digestion by trypsin and chymotrypsin followed by mass spectrometry ............................................................................................................................. 38 3.4 Molecular cloning .................................................................................................................. 38 3.4.1 General molecular cloning methods ............................................................................. 38 3.4.1.1 Transformation of bacterial cells ............................................................................... 38 3.4.1.2 Plasmid purification from bacterial cells ................................................................... 39 3.4.1.3 Agarose gel electrophoresis ...................................................................................... 39 3.4.1.4 DNA extraction from agarose gel .............................................................................. 39 3.4.1.5 Cloning primers ......................................................................................................... 39 3.4.1.6 Plasmids ..................................................................................................................... 40 3.4.1.7 Polymerase chain reaction ........................................................................................ 40 3.4.1.8 DNA digestion with restriction endonuclease ........................................................... 41 3.4.1.9 DNA ligation ............................................................................................................... 41 3.4.1.10 DNA quantification ................................................................................................ 41 3.4.1.11 Transfection protocol ............................................................................................ 42 3.4.2 Soluble BCMA generation.............................................................................................. 42 3.4.3 NF-κB
Load more

Recommended publications
  • Dysfunctional Γ-Secretase in Familial Alzheimer's Disease
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Neurochem Manuscript Author Res. Author Manuscript Author manuscript; available in PMC 2019 July 01. Published in final edited form as: Neurochem Res. 2019 January ; 44(1): 5–11. doi:10.1007/s11064-018-2511-1. Dysfunctional γ-secretase in familial Alzheimer’s disease Michael S. Wolfe Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas 66045 USA. Abstract Genetics strongly implicate the amyloid β-peptide (Aβ) in the pathogenesis of Alzheimer’s disease. Dominant missense mutation in the presenilins and the amyloid precursor protein (APP) cause early-onset familial Alzheimer’s disease (FAD). As presenilin is the catalytic component of the γ-secretase protease complex that produces Aβ from APP, mutation of the enzyme or substrate that produce Aβ leads to FAD. However, the mechanism by which presenilin mutations cause FAD has been controversial, with gain of function and loss of function offered as binary choices. This overview will instead present the case that presenilins are dysfunctional in FAD. γ-Secretase is a multi-functional enzyme that proteolyzes the APP transmembrane domain in a complex and processive manner. Reduction in a specific function—the carboxypeptidase trimming of initially formed long Aβ peptides containing most of the transmembrane domain to shorter secreted forms —is an emerging common feature of FAD-mutant γ-secretase complexes. Keywords amyloid; protease; genetics; biochemistry Introduction The deposition of extracellular amyloid plaques and neurofibrillary tangles in the brain are cardinal pathological features of Alzheimer’s disease (AD) (Goedert and Spillantini, 2006). The former are composed primarily of the amyloid β-peptide (Aβ), while the latter are comprised of filaments of the otherwise microtubule-associated protein tau.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Reduced Reelin Expression Accelerates Amyloid-ßplaque
    9228 • The Journal of Neuroscience, July 7, 2010 • 30(27):9228–9240 Neurobiology of Disease Reduced Reelin Expression Accelerates Amyloid-␤ Plaque Formation and Tau Pathology in Transgenic Alzheimer’s Disease Mice Samira Kocherhans,1* Amrita Madhusudan,1* Jana Doehner,1* Karin S. Breu,1 Roger M. Nitsch,2 Jean-Marc Fritschy,1 and Irene Knuesel1 1Institute of Pharmacology and Toxicology, University of Zurich, CH-8057 Zurich, Switzerland, and 2Division of Psychiatry Research, University of Zurich, CH-8008 Zurich, Switzerland In addition to the fundamental role of the extracellular glycoprotein Reelin in neuronal development and adult synaptic plasticity, alterations in Reelin-mediated signaling have been suggested to contribute to neuronal dysfunction associated with Alzheimer’s disease (AD). In vitro data revealed a biochemical link between Reelin-mediated signaling, Tau phosphorylation, and amyloid precursor protein (APP) processing. To directly address the role of Reelin in amyloid-␤ plaque and Tau pathology in vivo, we crossed heterozygous Reelin knock-out mice (reeler) with transgenic AD mice to investigate the temporal and spatial AD-like neuropathology. We demonstrate that a reduction in Reelin expression results in enhanced amyloidogenic APP processing, as indicated by the precocious production of amyloid-␤ peptides, the significant increase in number and size of amyloid-␤ plaques, as well as age-related aggravation of plaque pathology in double mutant compared with single AD mutant mice of both sexes. Numerous amyloid-␤ plaques accumulate in the hippocampal formation and neocortex of double mutants, precisely in layers with strongest Reelin expression and highest accumulation of Reelin plaques in aged wild-type mice. Moreover, concentric accumulations of phosphorylated Tau-positive neurons around amyloid-␤ plaques were evident in 15-month-old double versus single mutant mice.
    [Show full text]
  • Evaluating the Potential Therapeutic Role of Angiotensin Converting
    Evaluating the Potential Therapeutic Role of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Alzheimer’s Disease using a Drosophila Model by Sarah Gomes A thesis submitted in conformity with the requirements for the degree of Master of Science Institute of Medical Science University of Toronto © Copyright by Sarah Gomes 2017 Evaluating the Potential Therapeutic Role of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Alzheimer’s Disease using a Drosophila Model Sarah Gomes Master of Science Institute of Medical Science University of Toronto 2017 Abstract Presenilins (PS) play a role in familial Alzheimer’s disease (AD) and Notch signalling. In a genetic screen looking for modifiers of APP but not Notch, we identified Drosophila orthologs of Angiotensin Converting Enzyme (ACE). Interestingly, ACE polymorphisms are associated with AD and Apo-E, the best characterized risk factor for late-onset AD. Moreover, ACE inhibitors (ACE-I) delayed the onset of cognitive impairment and neurodegeneration in mice and humans. However, it remains unclear why ACE-I are beneficial in AD. Here, we explore the link between PS and ACE in a Drosophila model using genetics and pharmacology. We found that ACE disruption does not affect Notch related phenotypes. Moreover, we found that ACE-I and Angiotensin Receptor Blockers are beneficial in an AD Drosophila model. Since inhibition of ACE has no detrimental effects on Notch and modulates AD related phenotypes, it could provide an important therapeutic target for AD. ii Acknowledgments I would like to begin by thanking my supervisor, Gabrielle Boulianne, for her support and guidance. She has not only taught me how to think like a scientist, but also how to create a work- life balance.
    [Show full text]
  • Ubiquitinations in the Notch Signaling Pathway
    Int. J. Mol. Sci. 2013, 14, 6359-6381; doi:10.3390/ijms14036359 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review Ubiquitinations in the Notch Signaling Pathway Julien Moretti 1 and Christel Brou 2,* 1 Immunology Institute, Department of Medicine, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA; E-Mail: [email protected] 2 Institut Pasteur and CNRS URA 2582, Signalisation Moléculaire et Activation Cellulaire, 25 rue du Docteur Roux, 75724 Paris cedex 15, France * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +33-1-40-61-30-41 Fax: +33-1-40-61-30-40. Received: 1 February 2013; in revised form: 11 March 2013 / Accepted: 14 March 2013 / Published: 19 March 2013 Abstract: The very conserved Notch pathway is used iteratively during development and adulthood to regulate cell fates. Notch activation relies on interactions between neighboring cells, through the binding of Notch receptors to their ligands, both transmembrane molecules. This inter-cellular contact initiates a cascade of events eventually transforming the cell surface receptor into a nuclear factor acting on the transcription of specific target genes. This review highlights how the various processes undergone by Notch receptors and ligands that regulate the pathway are linked to ubiquitination events. Keywords: Notch; ubiquitination; deubiquitinating enzyme; signal transduction; trafficking 1. Introduction Development and maintenance of organs and tissues requires constant interaction and communication between cells. One of the major signaling pathways involved in cell-cell communication is the Notch pathway. This pathway is highly conserved in animals as distantly related as C.
    [Show full text]
  • Regulated Signaling and Alzheimer's Disease
    Chapter 4 γ-Secretase — Regulated Signaling and Alzheimer's Disease Kohzo Nakayama, Hisashi Nagase, Chang-Sung Koh and Takeshi Ohkawara Additional information is available at the end of the chapter http://dx.doi.org/10.5772/54230 1. Introduction Alzheimer’s disease (AD) is an incurable and progressive neurodegenerative disorder and the most common form of dementia that occurs with aging. The main hallmarks of this disease are the extracellular deposition of amyloid plaques and the intracellular aggregation of tangles in the brain [1, 2]. Although the causes of both the onset and progression of AD are still uncertain, much evidence, including results of genetic analysis, indicates that amyloid precursor protein (APP) itself and its proteolytic processing are responsible for AD. Indeed, familial forms of AD (FAD) have mutations [3] or a duplication of the APP gene [4] or mutations in the presenilin1 or 2 (PS1 or PS2) genes [5-7] that code for a catalytic component of the γ-secretase complex [8]. Although APP plays a central role in AD [1, 2], the physiological function of this membrane protein is not clear [9]. On the other hand, γ-secretase was first identified as a protease that cleaves APP within the transmembrane domain and produces amyloid-β (Aβ) peptides [10], which are the main constituent of amyloid plaques and are thought to be involved in AD pathogenesis. However, similar to the physiological functions of APP, those of γ-secretase are also still unclear [11, 12]. The signaling hypothesis suggests that the primary function of γ-secretase is to regulate signal‐ ing of type 1 membrane proteins (the amino terminus is extracellular, and the carboxy terminus is cytoplasmic); this was proposed by analogy of Notch signaling [13-15].
    [Show full text]
  • CSF-Apoer2 Fragments As a Read-Out of Reelin Signaling Distinct Patterns
    Clinica Chimica Acta 490 (2019) 6–11 Contents lists available at ScienceDirect Clinica Chimica Acta journal homepage: www.elsevier.com/locate/cca CSF-ApoER2 fragments as a read-out of reelin signaling: Distinct patterns in T sporadic and autosomal-dominant Alzheimer disease Inmaculada Lopez-Fonta,b,1, Guillermo Iborra-Lazaroa,b,1, Raquel Sánchez-Vallec, ⁎ ⁎ José-Luis Molinuevoc, Inmaculada Cuchillo-Ibañeza,b, , Javier Sáez-Valeroa,b, a Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, 03550 Sant Joan d'Alacant, Spain b Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain c Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, 08036 Barcelona, Spain ARTICLE INFO ABSTRACT Keywords: Reelin is a glycoprotein associated with synaptic plasticity and neurotransmission. The malfunctioning of reelin Reelin signaling in the brain is likely to contribute to the pathogenesis of Alzheimer's disease (AD). Reelin binding to ApoER2 Apolipoprotein E receptor 2 (ApoER2) activates downstream signaling and induces the proteolytic cleavage of Proteolytic fragment ApoER2, resulting in the generation of soluble fragments. To evaluate the efficiency of reelin signaling in AD,we CSF have quantified the levels of reelin and soluble ectodomain fragments of ApoER2 (ectoApoER2) inthecere- Autosomal-dominant AD brospinal fluid (CSF). CSF from sporadic AD patients (sAD; n = 14, age 54–83 years) had lower levels of ecto- Sporadic AD ApoER2 (~31% reduction; p = .005) compared to those in the age-matched controls (n = 10, age 61–80), and a higher reelin/ecto-ApoER2 ratio. In contrast, autosomal dominant AD patients, carriers of PSEN1 mutations (ADAD; n = 7, age 31–49 years) had higher ecto-ApoER2 levels (~109% increment; p = .001) and a lower reelin/ecto-ApoER2 ratio than the non-mutation carriers from the same families (n = 7, age 25–47 years).
    [Show full text]
  • Inhibition of Γ-Secretase Leads to an Increase in Presenilin-1
    Mol Neurobiol DOI 10.1007/s12035-017-0705-1 Inhibition of γ-Secretase Leads to an Increase in Presenilin-1 Aitana Sogorb-Esteve1,2 & María-Salud García-Ayllón1,2,3 & Marta Llansola4 & Vicente Felipo 4 & Kaj Blennow5,6 & Javier Sáez-Valero1,2 Received: 30 May 2017 /Accepted: 1 August 2017 # The Author(s) 2017. This article is an open access publication Abstract γ-Secretase inhibitors (GSIs) are potential ther- terminal fragment (CTF) of APP, C99, also triggered an apeutic agents for Alzheimer’s disease (AD); however, increase in PS1. Similar increases in PS1 were evident in trials have proven disappointing. We addressed the possi- primary neurons treated repeatedly (4 days) with DAPT or bility that γ-secretase inhibition can provoke a rebound with the GSI BMS-708163 (avagacestat). Likewise, rats effect, elevating the levels of the catalytic γ-secretase examined after 21 days administered with avagacestat subunit, presenilin-1 (PS1). Acute treatment of SH- (40 mg/kg/day) had more brain PS1. Sustained γ- SY5Y cells with the GSI LY-374973 (N-[N-(3,5- secretase inhibition did not exert a long-term effect on difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl es- PS1 activity, evident through the decrease in CTFs of ter, DAPT) augments PS1, in parallel with increases in APP and ApoER2. Prolonged avagacestat treatment of other γ-secretase subunits nicastrin, presenilin enhancer rats produced a subtle impairment in anxiety-like behav- 2, and anterior pharynx-defective 1, yet with no increase ior. The rebound increase in PS1 in response to GSIs must in messenger RNA expression. Over-expression of the C- be taken into consideration for future drug development.
    [Show full text]
  • Cathepsin K-Mediated Notch1 Activation Contributes to Neovascularization in Response to Hypoxia
    ARTICLE Received 10 Jan 2014 | Accepted 9 Apr 2014 | Published 4 Jun 2014 DOI: 10.1038/ncomms4838 Cathepsin K-mediated notch1 activation contributes to neovascularization in response to hypoxia Haiying Jiang1,2,3,*, Xian Wu Cheng1,4,5,6,*, Guo-Ping Shi7, Lina Hu1, Aiko Inoue1, Yumiko Yamamura4, Hongxian Wu4, Kyosuke Takeshita4, Xiang Li1,5, Zhe Huang1, Haizhen Song1,8, Masashi Asai9, Chang-Ning Hao4, Kazumasa Unno4, Teruhiro Koike2, Yoshiharu Oshida2, Kenji Okumura4, Toyoaki Murohara4 & Masafumi Kuzuya1 Cysteine proteases play important roles in pathobiology. Here we reveal that cathepsin K (CatK) has a role in ischaemia-induced neovascularization. Femoral artery ligation-induced ischaemia in mice increases CatK expression and activity, and CatK-deficient mice show impaired functional recovery following hindlimb ischaemia. CatK deficiency reduces the levels of cleaved Notch1 (c-Notch1), Hes1 Hey1, Hey2, vascular endothelial growth factor, Flt-1 and phospho-Akt proteins of the ischaemic muscles. In endothelial cells, silencing of CatK mimicked, whereas CatK overexpression enhanced, the levels of c-Notch1 and the expression of Notch downstream signalling molecules, suggesting CatK contributes to Notch1 processing and activates downstream signalling. Moreover, CatK knockdown leads to defective endothelial cell invasion, proliferation and tube formation, and CatK deficiency is associated with decreased circulating endothelial progenitor cells-like CD31 þ /c-Kit þ cells in mice following hindlimb ischaemia. Transplantation of bone marrow-derived mononuclear cells from CatK þ / þ mice restores the impairment of neovascularization in CatK À / À mice. We conclude that CatK may be a potential therapeutic target for ischaemic disease. 1 Department of Community Healthcare & Geriatrics, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Aichiken, Japan.
    [Show full text]
  • Nicastrin Functions to Sterically Hinder Γ-Secretase– PNAS PLUS Substrate Interactions Driven by Substrate Transmembrane Domain
    Nicastrin functions to sterically hinder γ-secretase– PNAS PLUS substrate interactions driven by substrate transmembrane domain David M. Bolduc, Daniel R. Montagna, Yongli Gu, Dennis J. Selkoe1, and Michael S. Wolfe1 Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 Edited by Benjamin F. Cravatt, The Scripps Research Institute, La Jolla, CA, and approved November 24, 2015 (received for review July 1, 2015) γ-Secretase is an intramembrane-cleaving protease that pro- γ-secretase cleavage of its substrates (11, 12). These facts suggest cesses many type-I integral membrane proteins within the lipid that the diverse families of I-CLiPs likely have evolved funda- bilayer, an event preceded by shedding of most of the substrate’s mentally different mechanisms by which they recognize and ectodomain by α-orβ-secretases. The mechanism by which cleave their substrates. γ-secretase selectively recognizes and recruits ectodomain-shed Presenilin/γ-secretase is the founding member of the aspartyl substrates for catalysis remains unclear. In contrast to previous family of I-CLiPs. The importance of γ-secretase function in reports that substrate is actively recruited for catalysis when its biology and medicine is highlighted by its cleavage of the notch remaining short ectodomain interacts with the nicastrin compo- family of receptors, which is required for cell fate determination nent of γ-secretase, we find that substrate ectodomain is entirely in all metazoans (2, 13–16), and of the amyloid precursor protein dispensable for cleavage. Instead, γ-secretase–substrate binding is (APP), which is centrally implicated in Alzheimer’s disease (AD) driven by an apparent tight-binding interaction derived from sub- (14, 17).
    [Show full text]
  • And VLDL Receptor
    International Journal of Molecular Sciences Review The Reelin Receptors Apolipoprotein E receptor 2 (ApoER2) and VLDL Receptor Paula Dlugosz and Johannes Nimpf * Department of Medical Biochemistry, Max F. Perutz Laboratories, Medical University Vienna, 1030 Vienna, Austria; [email protected] * Correspondence: [email protected], Tel.: +43-1-4277-61808, Fax: +43-1-4277-9618 Received: 28 August 2018; Accepted: 3 October 2018; Published: 9 October 2018 Abstract: Apolipoprotein E receptor 2 (ApoER2) and VLDL receptor belong to the low density lipoprotein receptor family and bind apolipoprotein E. These receptors interact with the clathrin machinery to mediate endocytosis of macromolecules but also interact with other adapter proteins to perform as signal transduction receptors. The best characterized signaling pathway in which ApoER2 and VLDL receptor (VLDLR) are involved is the Reelin pathway. This pathway plays a pivotal role in the development of laminated structures of the brain and in synaptic plasticity of the adult brain. Since Reelin and apolipoprotein E, are ligands of ApoER2 and VLDLR, these receptors are of interest with respect to Alzheimer’s disease. We will focus this review on the complex structure of ApoER2 and VLDLR and a recently characterized ligand, namely clusterin. Keywords: apolipoprotein E receptor 2; VLDL receptor; reelin; clusterin; Alzheimer’s disease 1. Introduction Apolipoprotein E receptor 2 (ApoER2) and VLDL receptor (VLDLR) belong to the low density lipoprotein receptor (LDLR) family, a class of type-I transmembrane receptors with high homology to their name-giving member the LDL receptor. Besides more distant members of this family, such as LRP 1, 1b, 2, 5, and 6; ApoER2, VLDLR, and LDLR have a superimposable structure indicating that the corresponding genes may have evolved from one single ancestor by gene duplication events and minor exon rearrangements.
    [Show full text]
  • Rethinking Gamma-Secretase Inhibitors for Treatment of Non-Small Cell Lung Cancer: Is Notch the Target?
    Author Manuscript Published OnlineFirst on August 13, 2018; DOI: 10.1158/1078-0432.CCR-18-1635 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Rethinking gamma-secretase inhibitors for treatment of non-small cell lung cancer: Is Notch the target? Sharon R. Pine, Ph.D. Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA Department of Pharmacology and Department of Medicine, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA Running title: Rethinking gamma secretase inhibitors Keywords: gamma secretase inhibitor, Notch, patient-derived xenograft, non-small cell lung cancer, targets Corresponding Author: Sharon R. Pine, Ph.D., Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, 08901. Phone (732) 235 9629; Fax (732) 235 8096; E-mail: [email protected] Support: This research was supported by the National Cancer Institute (NCI), National Institutes of Health (NIH) (R01CA190578 to SRP). Conflict of interest statement: None to disclose Word count: Translational Relevance, 116; Abstract, 217; Manuscript, 2,522 Number of figures: 1 figure 1 Downloaded from clincancerres.aacrjournals.org on September 29, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 13, 2018; DOI: 10.1158/1078-0432.CCR-18-1635 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Translational Relevance Non-small cell lung cancer is responsible for one-fourth of cancer deaths. Although targeted therapy is available for a subset of patients and immunotherapy has recently become a standard- of-care, the death toll due to NSCLC has not decreased much.
    [Show full text]